Condition
HER2-positive Advanced Solid Tumor
Total Trials
3
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 1 (3)
Trial Status
Unknown1
Recruiting1
Enrolling By Invitation1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05150691Phase 1RecruitingPrimary
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05423977Phase 1Enrolling By InvitationPrimary
Study of ZV0203 in Patients With HER2-Positive Advanced Solid Tumors
NCT04450732Phase 1Unknown
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
Showing all 3 trials